LAS 33815
Latest Information Update: 28 Aug 2002
At a glance
- Originator Almirall-Prodesfarma
- Class Antirheumatics; Nonsteroidal anti-inflammatories
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 27 Jan 1999 New profile
- 27 Jan 1999 Phase-I clinical trials for Rheumatoid arthritis in Spain (Unknown route)